Technical Data
Rosiglitazone maleate (BRL 49653, HSDB 7555, TDZ 01, Rosiglitazone XR, Avandia, PPAR Agonist X, PPARg Agonist IX)
Biochemicals Storage: +4C/+4CShipping: Blue Ice
Same activities as rosaglitazone but different formulation Antidiabetic, hypoglycemic agent. Potent and selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist. Potent insulin sensitizing agent binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Ameliorates insulin resistance. Improves blood pressure and vascular function. Enhances proliferation of endogenous neural progenitor cells (NPCs). Anti-inflammatory compound. Has controversial therapeutic effects on the cardiovascular system.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: +4C
Stable for at least 2 years after receipt when stored at +4C. Stock solutions are stable for at least 3 months when stored at -20C.

CAS Number:

Molecular Formula:
C18H19N3O3S . C4H4O4

Molecular Weight:
Purity: >98% (HPLC)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
[[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
Rosiglitazone: J.A. Balfour & G.L. Plosker; Drugs 57, 921 (1999) (Review)
Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes: G.A. Knock, et al.; Eur. J. Pharmacol. 368, 103 (1999)
Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes: A. Cheng-Lai & A. Levine; Heart Dis. 2, 326 (2000) (Review)
Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review: J.M. Malinowski & S. Bolesta; Clin. Ther. 22, 1151 (2000) (Review)
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice: M.J. Ryan, et al.; Hypertension 3, 661 (2004)
Rosiglitazone: a review of its use in type 2 diabetes mellitus: E.D. Deeks & S.J. Keam; Drugs 67, 2747 (2007) (Review)
Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury: Q.Q. Meng, et al.; Neurosci. Lett. 503, 191 (2011)
Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells: W.M. Wang, et al.; Am. J. Nephrol. 34, 152 (2011)
PPARgamma agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway: Y. Ji, et al.; Cytokine 55, 409 (2011)
PPARgamma activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? S. Palee, et al.; World J. Cardiol. 3, 144 (2011)

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.